bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
Authors: Matas-Céspedes Alba , Rodriguez Vanina , Kalko Susana G. , Vidal-Crespo Anna , Rosich Laia , Casserras Teresa , Balsas Patricia , Villamor Neus , Giné Eva , Campo Elías , Roué Gaël , López-Guillermo Armando , Colomer Dolors , Pérez-Galán Patricia
Published: April 2023

PDF file - 588K, GSEA identified gene sets related to angiogenesis, adhesion, migration and serum-like responses.
Data Supplement from Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis
Authors: Liu Zhaojun , Zhang Jun , Gao Yanhong , Pei Lirong , Zhou Jing , Gu Liankun , Zhang Lianhai , Zhu Budong , Hattori Naoko , Ji Jiafu , Yuasa Yasuhito , Kim Wooho , Ushijima Toshikazu , Shi Huidong , Deng Dajun
Published: April 2023

Supplementary Table S1. Clinicopathological information of 8 patients with GCs used in methylome analysis.
Data Supplement from Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis
Authors: Liu Zhaojun , Zhang Jun , Gao Yanhong , Pei Lirong , Zhou Jing , Gu Liankun , Zhang Lianhai , Zhu Budong , Hattori Naoko , Ji Jiafu , Yuasa Yasuhito , Kim Wooho , Ushijima Toshikazu , Shi Huidong , Deng Dajun
Published: April 2023

Supplementary Table S2. List of CpG islands of the 73 candidate genes selected for methylation analysis by DHPLC.
Data Supplement from Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis
Authors: Liu Zhaojun , Zhang Jun , Gao Yanhong , Pei Lirong , Zhou Jing , Gu Liankun , Zhang Lianhai , Zhu Budong , Hattori Naoko , Ji Jiafu , Yuasa Yasuhito , Kim Wooho , Ushijima Toshikazu , Shi Huidong , Deng Dajun
Published: April 2023

Supplementary Materials and Methods. Primer sequences, PCR condition, bisulfite-sequencing, tissue microarray, immunohistochemical staining.
Supplemental Figure 2 from An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2
Authors: Cardnell Robert J.G. , Behrens Carmen , Diao Lixia , Fan YouHong , Tang Ximing , Tong Pan , Minna John D. , Mills Gordon B. , Heymach John V. , Wistuba Ignacio I. , Wang Jing , Byers Lauren A.
Published: April 2023

Supplemental Figure 2. Unsupervised hierarchical clustering of mRNA in LUAD.
Supplementary Figure 4 from Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers
Authors: Hu Hanguang , Zhang Hang , Ge Weiting , Liu Xiyong , Loera Sofia , Chu Peiguo , Chen Huarong , Peng Jiaping , Zhou Lun , Yu Shujing , Yuan Ying , Zhang Suzhan , Lai Lily , Yen Yun , Zheng Shu
Published: April 2023

PDF file, 234K, Expression of SPARCL1 in RKO cells reduced tumor growth in xenograft mouse models.
Supplementary Figure 3 from Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers
Authors: Hu Hanguang , Zhang Hang , Ge Weiting , Liu Xiyong , Loera Sofia , Chu Peiguo , Chen Huarong , Peng Jiaping , Zhou Lun , Yu Shujing , Yuan Ying , Zhang Suzhan , Lai Lily , Yen Yun , Zheng Shu
Published: April 2023

PDF file, 379K, Recombinant human SPARCL1 protein reversed malignant phenotypes colon cancer cells in vitro.
Supplementary Tables 1 - 2 from Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
Authors: Kennedy-Nasser Alana A. , Ku Stephanie , Castillo-Caro Paul , Hazrat Yasmin , Wu Meng-Fen , Liu Hao , Melenhorst Jos , Barrett A. John , Ito Sawa , Foster Aaron , Savoldo Barbara , Yvon Eric , Carrum George , Ramos Carlos A. , Krance Robert A. , Leung Kathryn , Heslop Helen E. , Brenner Malcolm K. , Bollard Catherine M.
Published: April 2023

PDF file - 63KB, Supplemental Table 1. Recipients of MRD Grafts who did not receive ULD-IL-2 Supplemental Table 2. Recipients of MUD Grafts who did not receive ULD-IL-2.
Supplemental Table 2 from Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
Authors: Merchant Melinda S. , Bernstein Donna , Amoako Martha , Baird Kristin , Fleisher Thomas A. , Morre Michel , Steinberg Seth M. , Sabatino Marianna , Stroncek Dave F. , Venkatasan Aradhana M. , Wood Bradford J. , Wright Matthew , Zhang Hua , Mackall Crystal L.
Published: April 2023

T Cell doses administered in autologous lymphocyte infusions.
Supplemental Figure 2 from Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
Authors: Merchant Melinda S. , Bernstein Donna , Amoako Martha , Baird Kristin , Fleisher Thomas A. , Morre Michel , Steinberg Seth M. , Sabatino Marianna , Stroncek Dave F. , Venkatasan Aradhana M. , Wood Bradford J. , Wright Matthew , Zhang Hua , Mackall Crystal L.
Published: April 2023

DC phenotypes reveal consistent pattern of activation.
Supplemental Figure 1 from Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
Authors: Merchant Melinda S. , Bernstein Donna , Amoako Martha , Baird Kristin , Fleisher Thomas A. , Morre Michel , Steinberg Seth M. , Sabatino Marianna , Stroncek Dave F. , Venkatasan Aradhana M. , Wood Bradford J. , Wright Matthew , Zhang Hua , Mackall Crystal L.
Published: April 2023

OS and EFS for all patients enrolled and PFS according to histologic group
Supplementary Methods and Figure Legend from β-1,4-Galactosyltransferase III Enhances Invasive Phenotypes Via β1-Integrin and Predicts Poor Prognosis in Neuroblastoma
Authors: Chang Hsiu-Hao , Chen Chia-Hua , Chou Chih-Hsing , Liao Yung-Feng , Huang Miao-Juei , Chen Ya-Hsin , Wang Wei-Jen , Huang John , Hung Ji-Shiang , Ho Wan-Ling , Jeng Yung-Ming , Che Mei-Ieng , Lee Hsinyu , Lu Meng-Yao , Yang Yung-Li , Jou Shiann-Tarng , Lin Dong-Tsamn , Lin Kai-Hsin , Hsu Wen-Ming , Huang Min-Chuan
Published: April 2023

PDF file - 144K
Supplementary Figure 7 from To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN
Authors: Shiwarski Daniel J. , Shao Chunbo , Bill Anke , Kim Jean , Xiao Dong , Bertrand Carol A. , Seethala Raja S. , Sano Daisuke , Myers Jeffery N. , Ha Patrick , Grandis Jennifer , Gaither L. Alex , Puthenveedu Manojkumar A. , Duvvuri Umamaheswar
Published: April 2023

PDF file - 267K, Proposed model describing the role of TMEM16A in tumor progression.
Supplementary Figure 5 from β-1,4-Galactosyltransferase III Enhances Invasive Phenotypes Via β1-Integrin and Predicts Poor Prognosis in Neuroblastoma
Authors: Chang Hsiu-Hao , Chen Chia-Hua , Chou Chih-Hsing , Liao Yung-Feng , Huang Miao-Juei , Chen Ya-Hsin , Wang Wei-Jen , Huang John , Hung Ji-Shiang , Ho Wan-Ling , Jeng Yung-Ming , Che Mei-Ieng , Lee Hsinyu , Lu Meng-Yao , Yang Yung-Li , Jou Shiann-Tarng , Lin Dong-Tsamn , Lin Kai-Hsin , Hsu Wen-Ming , Huang Min-Chuan
Published: April 2023

PDF file - 42K, Effects of B4GALT3 on NB cell migration and invasion
Supplementary Figure 3 from To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN
Authors: Shiwarski Daniel J. , Shao Chunbo , Bill Anke , Kim Jean , Xiao Dong , Bertrand Carol A. , Seethala Raja S. , Sano Daisuke , Myers Jeffery N. , Ha Patrick , Grandis Jennifer , Gaither L. Alex , Puthenveedu Manojkumar A. , Duvvuri Umamaheswar
Published: April 2023

PDF file - 472K, Over expression of TMEM16A in T24 cancer cells decreases motility and invasion.
Supplementary Figure 10 from β-1,4-Galactosyltransferase III Enhances Invasive Phenotypes Via β1-Integrin and Predicts Poor Prognosis in Neuroblastoma
Authors: Chang Hsiu-Hao , Chen Chia-Hua , Chou Chih-Hsing , Liao Yung-Feng , Huang Miao-Juei , Chen Ya-Hsin , Wang Wei-Jen , Huang John , Hung Ji-Shiang , Ho Wan-Ling , Jeng Yung-Ming , Che Mei-Ieng , Lee Hsinyu , Lu Meng-Yao , Yang Yung-Li , Jou Shiann-Tarng , Lin Dong-Tsamn , Lin Kai-Hsin , Hsu Wen-Ming , Huang Min-Chuan
Published: April 2023

PDF file - 93K, B4GALT3 modulates protein levels of mature β1 integrin in SK-N-AS and SK-N-BE cells
Supplementary Figure 1 from To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN
Authors: Shiwarski Daniel J. , Shao Chunbo , Bill Anke , Kim Jean , Xiao Dong , Bertrand Carol A. , Seethala Raja S. , Sano Daisuke , Myers Jeffery N. , Ha Patrick , Grandis Jennifer , Gaither L. Alex , Puthenveedu Manojkumar A. , Duvvuri Umamaheswar
Published: April 2023

PDF file - 78K, TMEM16A expression levels in primary SCCHN does not correlate with the presence of nodal metastases.
Supplementary Methods and Materials, Figures S1-S3, Tables S1-S5 from Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Authors: Kim Han Sang , Kwon Hyeong Ju , Jung Inkyung , Yun Mi Ran , Ahn Myung-Ju , Kang Byung Woog , Sun Jong-Mu , Kim Sung Bae , Yoon Dok-Hyun , Park Keon Uk , Lee Se-Hoon , Koh Yoon Woo , Kim Se Hun , Choi Eun Chang , Koo Dong Hoe , Sohn Jin Hee , Kim Bomi , Kwon Nak-Jung , Yun Hwan Jung , Lee Min Goo , Lee Ji Hyun , Kim Tae-Min , Kim Hye Ryun , Kim Joo Hang , Paik Soonmyung , Cho Byoung Chul
Published: April 2023

Supplementary Methods and Materials, Figures S1-S3, Tables S1-S5. 1. Supplementary Methods. page 2-4 -Gene set analysis for gene expression data -Immunohistochemistry and fluorescent in situ hybridization (FISH) -Enzyme-linked immunosorbent assay (ELISA) 2. Supplemental Figures. Figure S1: CONSORT diagram. page 5 Figure S2: Kaplan-Meier estimates of progression-free survival and overall survival according to p16 status. page 6 Figure S3: Analysis of fibroblast growth factor receptor 1 (FGFR1) gene amplification by fluorescent in situ hybridization. page 7 3. Supplemental Tables Table S1: Gene list and platforms for biomarker analysis. page 8-12 Table S2: Loci information of somatic mutations. page 13 Table S3: Gene expression profile in 230 cancer genes. page 14-20 Table S4: Gene set enrichment analysis. page 21-22 Table S5: Copy number aberrations in 86 cancer genes. page 23
Supplementary Figure 3 from The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Authors: Carol Hernan , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

PDF file - 17403K, Histological confirmation of leukemic infiltrates of murine tissues at necropsy. H&E staining of tissues collected from (A) non-engrafted mouse; or mice engrafted with ALL-19 and treated with: (B) VXL/SAR3419 x 3 or (C) VXL/SAR3419 extended treatment. BM, bone marrow Spl, spleen; Br: brain. The gray solid bar in the low left corner indicates size (200 μm).
Supplementary Figure 2 from The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Authors: Carol Hernan , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

PDF file - 2999K, SAR3419 is effective against BCP-ALL xenografts in vivo over a broad dose range. Mice engrafted with ALL-4 (A) were treated with vehicle control (dotted black line), or SAR3419 at 10 mg/kg (solid red line), 7.5 mg/kg (solid green line), 5 mg/kg (solid blue line), 2.5 mg/kg (solid orange line) or with the unconjugated MAb huB4 (gray dotted line) while mice engrafted with ALL-19 (B) were treated with vehicle control (dotted black line), or SAR3419 at 10 mg/kg (solid red line) and at 1.0 mg/kg (solid blue line). Response to treatment was monitored by weekly enumeration of the proportion of %huCD45+ cells in the PB of individual mice (left panels), and Kaplan-Meier analysis of EFS (right panels). Gray arrows indicate treatment time points.
Supplementary Figure 1 from The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Authors: Carol Hernan , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

PDF file - 3285K, Single agent efficacy of SAR3419. NOD/SCID mice engrafted with ALL-16 (A); ALL-17 (B); or MLL-14 (C) were treated with vehicle (dashed lines) or 10 mg/kg SAR3419 (solid lines) once a week for 3 weeks. The response to treatment was monitored by weekly measurements of the %huCD45+ cells in PB of individual mice (left panel). The EFS (time to reach 25% of leukemia cells in PB) is represented by Kaplan-Meier plots (right panel). Gray arrows indicate treatment time points.
Supplemental Appendix 1 from Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Authors: Hassan Raffit , Kindler Hedy L. , Jahan Thierry , Bazhenova Lyudmila , Reck Martin , Thomas Anish , Pastan Ira , Parno Jeff , O'Shannessy Daniel J. , Fatato Penny , Maltzman Julia D. , Wallin Bruce A.
Published: April 2023

Dose adjustments.
Supplementary Figure 4 from CADM1 Expression and Stepwise Downregulation of CD7 Are Closely Associated with Clonal Expansion of HTLV-I–Infected Cells in Adult T-cell Leukemia/Lymphoma
Authors: Kobayashi Seiichiro , Nakano Kazumi , Watanabe Eri , Ishigaki Tomohiro , Ohno Nobuhiro , Yuji Koichiro , Oyaizu Naoki , Asanuma Satomi , Yamagishi Makoto , Yamochi Tadanori , Watanabe Nobukazu , Tojo Arinobu , Watanabe Toshiki , Uchimaru Kaoru
Published: April 2023

PDF file - 41KB, Temporal changes in the data of a chronic-type ATL patient.
Supplementary Table 4 from Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas
Authors: Eruslanov Evgeniy , Stoffs Taryn , Kim Wan-Ju , Daurkin Irina , Gilbert Scott M. , Su Li-Ming , Vieweg Johannes , Daaka Yehia , Kusmartsev Sergei
Published: April 2023

PDF file - 57K, Summary statistics for Fig.4A
Data Supplement from Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts
Authors: Cottu Paul , Bièche Ivan , Assayag Franck , El Botty Rania , Chateau-Joubert Sophie , Thuleau Aurélie , Bagarre Thomas , Albaud Benoit , Rapinat Audrey , Gentien David , de la Grange Pierre , Sibut Vonick , Vacher Sophie , Hatem Rana , Servely Jean-Luc , Fontaine Jean-Jacques , Decaudin Didier , Pierga Jean-Yves , Roman-Roman Sergio , Marangoni Elisabetta
Published: April 2023

Supplementary Figure S1. Representative sections of TMA corresponding to HBCx22 OvaR xenograft.
Data Supplement from Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts
Authors: Cottu Paul , Bièche Ivan , Assayag Franck , El Botty Rania , Chateau-Joubert Sophie , Thuleau Aurélie , Bagarre Thomas , Albaud Benoit , Rapinat Audrey , Gentien David , de la Grange Pierre , Sibut Vonick , Vacher Sophie , Hatem Rana , Servely Jean-Luc , Fontaine Jean-Jacques , Decaudin Didier , Pierga Jean-Yves , Roman-Roman Sergio , Marangoni Elisabetta
Published: April 2023

Supplementary Table S1. Statistical analysis of tumor growth inhibition (TGI).
Supplementary Figure 1 from Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas
Authors: Eruslanov Evgeniy , Stoffs Taryn , Kim Wan-Ju , Daurkin Irina , Gilbert Scott M. , Su Li-Ming , Vieweg Johannes , Daaka Yehia , Kusmartsev Sergei
Published: April 2023

PDF file - 169K, CCR8 expression in myeloid cells isolated from blood of cancer patients
Data Supplement from Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts
Authors: Cottu Paul , Bièche Ivan , Assayag Franck , El Botty Rania , Chateau-Joubert Sophie , Thuleau Aurélie , Bagarre Thomas , Albaud Benoit , Rapinat Audrey , Gentien David , de la Grange Pierre , Sibut Vonick , Vacher Sophie , Hatem Rana , Servely Jean-Luc , Fontaine Jean-Jacques , Decaudin Didier , Pierga Jean-Yves , Roman-Roman Sergio , Marangoni Elisabetta
Published: April 2023

Supplementary Table S5. Genes differentially expressed between HBCx34 TamR and HBCx34 and associated gene ontology terms.
Supplementary Table 1 from Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Authors: Iglesia Michael D. , Vincent Benjamin G. , Parker Joel S. , Hoadley Katherine A. , Carey Lisa A. , Perou Charles M. , Serody Jonathan S.
Published: April 2023

PDF file - 33K, Multivariate survival analysis p values.
Supplementary figure 1 from TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Authors: Peeters Sarah G.J.A. , Zegers Catharina M.L. , Biemans Rianne , Lieuwes Natasja G. , van Stiphout Ruud G.P.M. , Yaromina Ala , Sun Jessica D. , Hart Charles P. , Windhorst Albert D. , van Elmpt Wouter , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary figure 1. A) Treatment schedule for the rhabdomyosarcoma and H460 models. All animals were randomized over either the treatment or the control group. These groups were both treated with either NaCl or TH-302 (rhabdomysarcoma 25mg/kg, H460 50mg/kg). Rhabdomyosarcoma bearing animals started with oxygen modification at day 0 and a [18F]HX4 hypoxia PET scan. For histological controls only, this scan was repeated on day 4. Animals from the treatment group were exposed to radiotherapy (RT) at the end of treatment day 3 and their tumor volume was monitored until 4 times start volume was reached. H460 tumor bearing animals from the histological control group were injected with pimonidazole and Hoechst on the last treatment day and sacrificed. Animals from the treatment group were exposed to radiotherapy at day 4 and monitored until a tumor volume of 4 times start treatment volume was reached.
Supplementary Table 7 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
Authors: Parry Marina , Rose-Zerilli Matthew J.J. , Ljungström Viktor , Gibson Jane , Wang Jun , Walewska Renata , Parker Helen , Parker Anton , Davis Zadie , Gardiner Anne , McIver-Brown Neil , Kalpadakis Christina , Xochelli Aliki , Anagnostopoulos Achilles , Fazi Claudia , Gonzalez de Castro David , Dearden Claire , Pratt Guy , Rosenquist Richard , Ashton-Key Margaret , Forconi Francesco , Collins Andrew , Ghia Paolo , Matutes Estella , Pangalis Gerassimos , Stamatopoulos Kostas , Oscier David , Strefford Jonathan C.
Published: April 2023

Supplementary Table 7. Therapies regimes use to treat SMZL patients in this study
Supplementary Figure S4 from CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells
Authors: Wang Xiuli , Wong ChingLam W. , Urak Ryan , Mardiros Armen , Budde Lihua E. , Chang Wen-Chung , Thomas Sandra H. , Brown Christine E. , La Rosa Corinna , Diamond Don J. , Jensen Michael C. , Nakamura Ryotaro , Zaia John A. , Forman Stephen J.
Published: April 2023

Supplementary Figure S4. Enhanced anti-tumor activity of adoptively transferred bi-specific T cells by CMV vaccine for replased tumor
Supplementary Figure S1 from CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells
Authors: Wang Xiuli , Wong ChingLam W. , Urak Ryan , Mardiros Armen , Budde Lihua E. , Chang Wen-Chung , Thomas Sandra H. , Brown Christine E. , La Rosa Corinna , Diamond Don J. , Jensen Michael C. , Nakamura Ryotaro , Zaia John A. , Forman Stephen J.
Published: April 2023

Supplementary Figure S1. Schematic of the CD19CAR-T2A-EGFRt lentiviral vector
Supplementary Figure 2 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
Authors: Parry Marina , Rose-Zerilli Matthew J.J. , Ljungström Viktor , Gibson Jane , Wang Jun , Walewska Renata , Parker Helen , Parker Anton , Davis Zadie , Gardiner Anne , McIver-Brown Neil , Kalpadakis Christina , Xochelli Aliki , Anagnostopoulos Achilles , Fazi Claudia , Gonzalez de Castro David , Dearden Claire , Pratt Guy , Rosenquist Richard , Ashton-Key Margaret , Forconi Francesco , Collins Andrew , Ghia Paolo , Matutes Estella , Pangalis Gerassimos , Stamatopoulos Kostas , Oscier David , Strefford Jonathan C.
Published: April 2023

Supplementary Figure 2. ABSOLUTE
Supplemental Figures 1 - 7 from EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Authors: Ercan Dalia , Choi Hwan Geun , Yun Cai-Hong , Capelletti Marzia , Xie Ting , Eck Michael J. , Gray Nathanael S. , Jänne Pasi A.
Published: April 2023

Supplemental Figures 1 - 7. Figure S1. Sequence tracings from WZ4002 resistant Ba/F3 cells demonstrating EGFR L718Q, C797S and L844V mutations. Figure S2. EGFR Del19 Ba/F3 cells alone or expressing EGFR L718Q were treated with EGF. Figure S3. Structure of TX 2-30. Figure S4. Impact of EGFR L718Q and L844V on sensitivity to WZ4002 and quinazoline based EGFR inhibitors Figure S5. Impact of EGFR Q791R mutation. Figure S6. EGFR L718Q and L844V cause resistance in trans in EGFR mutant NSCLC cell lines. Figure S7. Evaluation of cetuximab on EGFR dimerization and growth in EGFR C797S expressing cells.
Supplemental Figure legends from EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Authors: Ercan Dalia , Choi Hwan Geun , Yun Cai-Hong , Capelletti Marzia , Xie Ting , Eck Michael J. , Gray Nathanael S. , Jänne Pasi A.
Published: April 2023

Supplemental Figure legends. This file contains the detailed descriptions of the supplementaal figures.
Supplemental table S2 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study
Authors: Fox Peter , Balleine Rosemary L. , Lee Clara , Gao Bo , Balakrishnar Bavanthi , Menzies Alexander M. , Yeap Shang Heng , Ali Sayed Sahanawaz , Gebski Val , Provan Pamela , Coulter Sally , Liddle Christopher , Hui Rina , Kefford Richard , Lynch Jodi , Wong Mark , Wilcken Nicholas , Gurney Howard
Published: April 2023

Frequency of CYP2D6 alleles in study subjects compared to published frequencies for selected race/ ethnic groups
Supplementary Table S2 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
Authors: Rao Mahadev , Atay Scott M. , Shukla Vivek , Hong Young , Upham Trevor , Ripley R. Taylor , Hong Julie A. , Zhang Mary , Reardon Emily , Fetsch Patricia , Miettinen Markku , Li Xinmin , Peer Cody J. , Sissung Tristan , Figg William D. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

Genes Modulated by MM (25 or 100nM) and SP1knockdown/p53 over-expression in MES1 and/or MES7 Cells.
Supplementary Table S1 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
Authors: Rao Mahadev , Atay Scott M. , Shukla Vivek , Hong Young , Upham Trevor , Ripley R. Taylor , Hong Julie A. , Zhang Mary , Reardon Emily , Fetsch Patricia , Miettinen Markku , Li Xinmin , Peer Cody J. , Sissung Tristan , Figg William D. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

Genes Simultaneously Modulated in Cultured MES1 and MES7 Cells and Xenografts following Mithramycin Treatment.
Suppl Figures from A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
Authors: Wick Wolfgang , Fricke Harald , Junge Klaus , Kobyakov Grigory , Martens Tobias , Heese Oliver , Wiestler Benedikt , Schliesser Maximilian G. , von Deimling Andreas , Pichler Josef , Vetlova Elena , Harting Inga , Debus Jürgen , Hartmann Christian , Kunz Claudia , Platten Michael , Bendszus Martin , Combs Stephanie E.
Published: April 2023

Suppl Figures S1-S4. S1: Genomic Localization of the CpG2 in the CD95 L promoter. S2: Survival probability according to CpG2 methylation status. S3: Survival probability according to CD95L expression as detected by IHC. S4 a and b: Cox regression data for CpG1 and 2 in the CD95L promoter.
Supplementary Figure 3 from Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens
Authors: Kim Won , Zhang Li , Wilton John H. , Fetterly Gerald , Mohler James L. , Weinberg Vivian , Morse Allison , Szmulewitz Russell Z. , Friedlander Terence W. , Fong Lawrence , Lin Amy M. , Harzstark Andrea L. , Molina Arturo , Small Eric J. , Ryan Charles J.
Published: April 2023

Supplementary Figure 3. Boxplots: PSA response versus baseline circulating androgen levels: DHEA, T and ASD
Supplementary Figure 2 from Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens
Authors: Kim Won , Zhang Li , Wilton John H. , Fetterly Gerald , Mohler James L. , Weinberg Vivian , Morse Allison , Szmulewitz Russell Z. , Friedlander Terence W. , Fong Lawrence , Lin Amy M. , Harzstark Andrea L. , Molina Arturo , Small Eric J. , Ryan Charles J.
Published: April 2023

Supplementary Figure 2. Boxplot: PSA response versus time on duration of prior ketoconazole
Supplementary Figure 3 from Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma
Authors: Nguyen Phu Hung , Giraud Julie , Chambonnier Lucie , Dubus Pierre , Wittkop Linda , Belleannée Geneviève , Collet Denis , Soubeyran Isabelle , Evrard Serge , Rousseau Benoit , Senant-Dugot Nathalie , Mégraud Francis , Mazurier Frédéric , Varon Christine
Published: April 2023

Effect of verapamil treatment in combination with dose-dependent chemotherapies on gastric cancer cell lines viability.
Supplementary tables from S1-S6 from miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma
Authors: Shi Yu , Chen Cong , Yu Shi-Zhu , Liu Qing , Rao Jun , Zhang Hua-Rong , Xiao Hua-Liang , Fu Ti-Wei , Long Hua , He Zhi-Cheng , Zhou Kai , Yao Xiao-Hong , Cui You-Hong , Zhang Xia , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

Supplementary tables from S1-S6.
Supplementary Figure 4 from Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma
Authors: Al-Ejeh Fares , Pajic Marina , Shi Wei , Kalimutho Murugan , Miranda Mariska , Nagrial Adnan M. , Chou Angela , Biankin Andrew V. , Grimmond Sean M. , Brown Michael P. , Khanna Kum Kum
Published: April 2023

Supplementary Figure 4: Efficacy of anti-EGFR directed RIT in combination therapy in vivo against PDAC model from the BxPC-3 ATCCTM cell lines. BxPC-3 cells expressing luciferase were used to inoculate balb/c nude mice subcutaneously at 4 weeks of age. Treatments were initiated when tumors reached 60 mm3 as outlined in diagram in A and in Figure 2. Single agent treatments included: EGFR control: 50 μg of unlabeled anti-EGFR mAb; Chk1i: 15 mg/kg of the Chk1 inhibitor PF-477736 administered as two 7.5 mg/kg injections per day subcutaneously on days 1, 4, 7 and 10; Gem: 50 mg/kg of gemcitabine administered intravenously on days 1, 4, 7 and 10; RIT: 177Lu-anti-EGFR mAb (50 μg with 6 MBq radioactivity per 20 g mouse) injected intravenously on day 2 only. For combinations, treatments were performed as described for the single agents where Chk1i was administered 3 hours before and after gemcitabine on days 1, 4, 7 and 10 and RIT was administered on day 2 only. (B) Tumor growth curves presented as the change in tumor volume compared to day 0 (% change +SEM, n = 5 mice per treatment group). (C) Representative images of live bioluminescence imaging using luciferin performed on day 1 (prior to treatment) and day 14 (96 hours after treatments). (D) Quantification and representative images of live bioluminescence imaging using caspase-3/7 substrate (Z-DEVD-Luciferase) performed on day 7 after treatment initiation. Data shown is the average of caspase-3/7 activation (+SEM, n = 5 per treatment group). *** p < 0.001 in One-way ANOVA in GraphPad® Prism.
Supplementary Figure S3 from miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma
Authors: Shi Yu , Chen Cong , Yu Shi-Zhu , Liu Qing , Rao Jun , Zhang Hua-Rong , Xiao Hua-Liang , Fu Ti-Wei , Long Hua , He Zhi-Cheng , Zhou Kai , Yao Xiao-Hong , Cui You-Hong , Zhang Xia , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

Supplementary Figure S3. Correlation between miR-663 and CXCR4 mRNA in grade II and III astrocytic glioma specimens.
Supplementary Figure S2 from miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma
Authors: Shi Yu , Chen Cong , Yu Shi-Zhu , Liu Qing , Rao Jun , Zhang Hua-Rong , Xiao Hua-Liang , Fu Ti-Wei , Long Hua , He Zhi-Cheng , Zhou Kai , Yao Xiao-Hong , Cui You-Hong , Zhang Xia , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

Supplementary Figure S2. Doxycycline treatment induces miR-663 expression in GBM cells transfected with miR-663 inducible lentiviral vectors.
Supplementary Figure S1 from miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma
Authors: Shi Yu , Chen Cong , Yu Shi-Zhu , Liu Qing , Rao Jun , Zhang Hua-Rong , Xiao Hua-Liang , Fu Ti-Wei , Long Hua , He Zhi-Cheng , Zhou Kai , Yao Xiao-Hong , Cui You-Hong , Zhang Xia , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

Supplementary Figure S1. Luciferase reporter assay of U87-MG cell transfected with miR-663 mimics or control oligomer, together with CXCR4-CDS wild-type reporter (CXCR4-CDS-wt) or the indicated mutant ones.
Supplementary Figure 1 from Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival
Authors: Reed Caroline M. , Cresce Nicole D. , Mauldin Ileana S. , Slingluff Craig L. , Olson Walter C.
Published: April 2023

Supplementary Figure 1. Positive control response to 6MHP peptide components.
Table S2 from Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy
Authors: Morita Rena , Hirohashi Yoshihiko , Torigoe Toshihiko , Ito-Inoda Satoko , Takahashi Akari , Mariya Tasuku , Asanuma Hiroko , Tamura Yasuaki , Tsukahara Tomohide , Kanaseki Takayuki , Kubo Terufumi , Kutomi Goro , Mizuguchi Toru , Terui Takeshi , Ishitani Kunihiko , Hashino Satoshi , Kondo Toru , Minagawa Nozomi , Takahashi Norihiko , Taketomi Akinobu , Todo Satoru , Asaka Masahiro , Sato Noriyuki
Published: April 2023

Summary of Colon cancer patients
Figure S4 from Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy
Authors: Morita Rena , Hirohashi Yoshihiko , Torigoe Toshihiko , Ito-Inoda Satoko , Takahashi Akari , Mariya Tasuku , Asanuma Hiroko , Tamura Yasuaki , Tsukahara Tomohide , Kanaseki Takayuki , Kubo Terufumi , Kutomi Goro , Mizuguchi Toru , Terui Takeshi , Ishitani Kunihiko , Hashino Satoshi , Kondo Toru , Minagawa Nozomi , Takahashi Norihiko , Taketomi Akinobu , Todo Satoru , Asaka Masahiro , Sato Noriyuki
Published: April 2023

Establishment of CIC-targeting immunotherapy using antigenic peptide derived from OR7C1.
Supplementary table 2 from A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer
Authors: Diaz-Lagares Angel , Mendez-Gonzalez Jesus , Hervas David , Saigi Maria , Pajares Maria J. , Garcia Diana , Crujerias Ana B. , Pio Ruben , Montuenga Luis M. , Zulueta Javier , Nadal Ernest , Rosell Antoni , Esteller Manel , Sandoval Juan
Published: April 2023

Primers for pyrosequencing and priority list.
Supplementary Figure 3 from A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer
Authors: Diaz-Lagares Angel , Mendez-Gonzalez Jesus , Hervas David , Saigi Maria , Pajares Maria J. , Garcia Diana , Crujerias Ana B. , Pio Ruben , Montuenga Luis M. , Zulueta Javier , Nadal Ernest , Rosell Antoni , Esteller Manel , Sandoval Juan
Published: April 2023

Differentially methylated levels in neighboring CpGs on the selected candidate genes.
Supplementary Figure 2 from A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer
Authors: Diaz-Lagares Angel , Mendez-Gonzalez Jesus , Hervas David , Saigi Maria , Pajares Maria J. , Garcia Diana , Crujerias Ana B. , Pio Ruben , Montuenga Luis M. , Zulueta Javier , Nadal Ernest , Rosell Antoni , Esteller Manel , Sandoval Juan
Published: April 2023

Epigenetic and expression analysis based on histological subtypes from primary tissues of the TCGA database.
Supplementary Figure 1 from A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer
Authors: Diaz-Lagares Angel , Mendez-Gonzalez Jesus , Hervas David , Saigi Maria , Pajares Maria J. , Garcia Diana , Crujerias Ana B. , Pio Ruben , Montuenga Luis M. , Zulueta Javier , Nadal Ernest , Rosell Antoni , Esteller Manel , Sandoval Juan
Published: April 2023

Flow chart indicating study design and biological and bioinformatic filters
Supplementary Table 5 from PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Authors: Field Matthew G. , Decatur Christina L. , Kurtenbach Stefan , Gezgin Gülçin , van der Velden Pieter A. , Jager Martine J. , Kozak Kaleigh N. , Harbour J. William
Published: April 2023

Gene ontology analysis of genes differentially expressed between Class1PRAME+ tumors and Class1PRAME- tumors.
Supplemental tables 1-6 from The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
Authors: Lolkema Martijn P. , Bohets Hilde H. , Arkenau Hendrik-Tobias , Lampo Ann , Barale Erio , de Jonge Maja J.A. , van Doorn Leni , Hellemans Peter , de Bono Johann S. , Eskens Ferry A.L.M.
Published: April 2023

Supplemental tables 1-6. Supplemental table 1: Patient Demographics and Baseline Characteristics. Supplemental table 2. Plasma Pharmacokinetic parameters. Supplemental table 3. Identification of metabolites of JNJ-38877605. Supplemental table 3. Identification of metabolites of JNJ-38877605. Supplementary table 5: noteworthy post-mortem changes â€“ 1-month recovery phase. Supplementary table 6: noteworthy microscopic changes (Probenecid study.
Supplementary Table 3 from PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Authors: Field Matthew G. , Decatur Christina L. , Kurtenbach Stefan , Gezgin Gülçin , van der Velden Pieter A. , Jager Martine J. , Kozak Kaleigh N. , Harbour J. William
Published: April 2023

Clinicopathologic and genomic features in the 12 patients with Class1met+ uveal melanomas.
Supplementary Table 1 from PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Authors: Field Matthew G. , Decatur Christina L. , Kurtenbach Stefan , Gezgin Gülçin , van der Velden Pieter A. , Jager Martine J. , Kozak Kaleigh N. , Harbour J. William
Published: April 2023

Molecular analyses and the order in which they were conducted in this study.
Supplementary Table 1, Supplementary Figures 1-7, Supplementary Materials and Methods from MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma
Authors: Mohan Suresh , Vander Broek Robert , Shah Sujay , Eytan Danielle F. , Pierce Matthew L. , Carlson Sophie G. , Coupar Jamie F. , Zhang Jialing , Cheng Hui , Chen Zhong , Van Waes Carter
Published: April 2023

Supplementary Table 1, Supplementary Figures 1-7, Supplementary Materials and Methods. Supplemental Table 1. Tumor, treatment, and outcome characteristics of human HNSCC lines Supplementary Figure 1. Boxplots of IC50s for 11 HPV- cell lines (red) and 8 HPV+ lines (cyan); Supplementary Figure 2. PF-384 effects on PI3K/mTOR, and MAPK/ERK pathways in UMSCC-46; Supplementary Figure 3 PF-384 effects on IKK-dependent phosphorylation of NF-κB p65 protein in UM-SCC-1 and 46; Supplementary Figure 4. Effects of PIK3CA knockdown on PI3K-AKT pathway and NF-κB signaling in UMSCC-1 and 46; Supplementary Figure 5. Effects of PF-384 and PD-901 treatment on weights of mice bearing UMSCC-1 xenografts; Supplementary Figure 6. Immunohistochemical staining of UMSCC-1 xenografts; Supplementary Figure 7. Schematic of PI3K/Akt/mTOR and MEK/ERK pathways and targets of PF-384 and PD-901
Supplementary Table 4 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
Authors: Markou Athina , Farkona Sofia , Schiza Christina , Efstathiou Tonia , Kounelis Sophia , Malamos Nikos , Georgoulias Vassilis , Lianidou Evi
Published: April 2023

Suppl.Table 4: PCR conditions and melting analysis protocols for each PIK3CA exon.
Supplemental Figure 6 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Authors: Jackson Christopher M. , Kochel Christina M. , Nirschl Christopher J. , Durham Nicholas M. , Ruzevick Jacob , Alme Angela , Francica Brian J. , Elias Jimmy , Daniels Andrew , Dubensky Thomas W. , Lauer Peter , Brockstedt Dirk G. , Baxi Emily G. , Calabresi Peter A. , Taube Janis M. , Pardo Carlos A. , Brem Henry , Pardoll Drew M. , Lim Michael , Drake Charles G.
Published: April 2023

B16-OVA brain tumors stimulate secretion of TGF-β1 from microglia. Cytokine concentrations in the supernatants from OT-1 cells co-cultured with (A) CD11c+ APCs isolated from the spleen at a ratio of 1:5, (B) APC from brain tumor draining lymph nodes at a ratio of 1:1, (C) and CD11b+/CD45-mid microglia isolated from the brain at a ratio of 1:5.
Supplementary Table 1 from PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
Authors: Markou Athina , Farkona Sofia , Schiza Christina , Efstathiou Tonia , Kounelis Sophia , Malamos Nikos , Georgoulias Vassilis , Lianidou Evi
Published: April 2023

Suppl. Table 1: Independent group: correlation of clinicopathological characteristics of breast cancer patients with clinically confirmed metastasis in respect to the presence of PIK3CA mutations in CTCs.
Figure S1 from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors
Authors: Montero Alberto J. , Kwon Deukwoo , Flores Aurea , Kovacs Krisztina , Trent Jonathan C. , Benedetto Pasquale , Rocha-Lima Caio , Merchan Jaime R.
Published: April 2023

Figure S1. Correlative Angiogenesis Biomarkers. A, levels of circulating endothelial cells in patients in schedule A and B at baseline (Pre-treatment). B, circulating endothelial precursor cells (EPCs) at baseline in patients in schedule A and B. C, baseline plasma angiogenic activity (PAA) at baseline in patients in schedule A and B.
Supplemental Figure 2 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Authors: Jackson Christopher M. , Kochel Christina M. , Nirschl Christopher J. , Durham Nicholas M. , Ruzevick Jacob , Alme Angela , Francica Brian J. , Elias Jimmy , Daniels Andrew , Dubensky Thomas W. , Lauer Peter , Brockstedt Dirk G. , Baxi Emily G. , Calabresi Peter A. , Taube Janis M. , Pardo Carlos A. , Brem Henry , Pardoll Drew M. , Lim Michael , Drake Charles G.
Published: April 2023

Brain tumors are more tolerogenic than flank or lung tumors. (A) Representative FACS plots from tumor draining lymph nodes of mice with B16-OVA brain, flank, or lung tumors. (B) Summary graphs of the percentage of daughter cells producing IFN-γ recovered from the tumor draining lymph nodes of mice with B16-OVA brain, flank, or lung tumors (5 mice/group).
The validation of over-expression of EID3 and down- regulation of EID3. from Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Authors: Munakata Koji , Uemura Mamoru , Tanaka Shinji , Kawai Kenji , Kitahara Tomohiro , Miyo Masaaki , Kano Yoshihiro , Nishikawa Shinpei , Fukusumi Takahito , Takahashi Yusuke , Hata Taishi , Nishimura Junichi , Takemasa Ichiro , Mizushima Tsunekazu , Ikenaga Masakazu , Kato Takeshi , Murata Kohei , Carethers John M. , Yamamoto Hirofumi , Doki Yuichiro , Mori Masaki
Published: April 2023

(A) The efficiency of over-expression was validated by expression of mRNA. The expression of EID3 was significantly higher in cells with EID3 ã€€expression vector than cells with control vector. (B) The efficiency of down-regulation was confirmed by mRNA. The expression of EID3 was significantly lower in cells with double-stranded RNA duplexes targeting human EID3 than cells with negative control siRNA. * p<0.05.
Supplementary Table 1-2 from Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance
Authors: Zhang Hanwei , Prado Kris , Zhang Kelvin X. , Peek Elizabeth M. , Lee Jane , Wang Xiaoyan , Huang Jiaoti , Li Gang , Pellegrini Matteo , Chin Arnold I.
Published: April 2023

Table 1 lists patient demographics of tumor microarray. Table 2 lists univariate and multivariate analysis of tumor microarray.
Supplementary Figure 2-10 from Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance
Authors: Zhang Hanwei , Prado Kris , Zhang Kelvin X. , Peek Elizabeth M. , Lee Jane , Wang Xiaoyan , Huang Jiaoti , Li Gang , Pellegrini Matteo , Chin Arnold I.
Published: April 2023

Supplementary Figure 2 shows representative histology of tumor microarray and provides controls for immunoblot, qPCR, and antibodies. Supplementary Figure 3 characterizes the created SW780 overexpressed cell lines. Supplementary Figure 4 shows sample immunofluorescence depicting FOXP3 localization. Supplementary Figure 5 shows SW780 RNA Seq alignment statistics. Supplementary Figure 6 shows migration assay in SW780 overexpressed cells. Supplementary Figure 7 shows FOXP3del3 network analyses. Supplementary Figure 8 shows FOXP3 knockdown efficiency. Supplementary Figure 9 shows HT1376 RNA Seq alignment statistics. Supplementary Figure 10 shows dendrogram between FOXP3 overexpressed cells and TCGA.
Supplementary Figure 1 from Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance
Authors: Zhang Hanwei , Prado Kris , Zhang Kelvin X. , Peek Elizabeth M. , Lee Jane , Wang Xiaoyan , Huang Jiaoti , Li Gang , Pellegrini Matteo , Chin Arnold I.
Published: April 2023

Supplementary Figure 1 lists the sequencing gene alignments separated into exons and depicting primer pairs used.
Supplemental Table S1 from Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
Authors: Hirbe Angela C. , Dahiya Sonika , Miller Christopher A. , Li Tiandao , Fulton Robert S. , Zhang Xiaochun , McDonald Sandra , DeSchryver Katherine , Duncavage Eric J. , Walrath Jessica , Reilly Karlyne M. , Abel Haley J. , Pekmezci Melike , Perry Arie , Ley Timothy J. , Gutmann David H.
Published: April 2023

Supplemental Table S1. Plasmids Used
Supplementary Table 1 from Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy
Authors: Catalano Stefania , Campana Antonella , Giordano Cinzia , Győrffy Balázs , Tarallo Roberta , Rinaldi Antonio , Bruno Giuseppina , Ferraro Aurora , Romeo Francesco , Lanzino Marilena , Naro Fabio , Bonofiglio Daniela , Andò Sebastiano , Barone Ines
Published: April 2023

Characteristic of breast cancer cohort.
Supplementary Figures 1 - 4 from LIM and SH3 Protein 1 Induces TGFβ-Mediated Epithelial–Mesenchymal Transition in Human Colorectal Cancer by Regulating S100A4 Expression
Authors: Wang Hui , Shi Jiaolong , Luo Yuhao , Liao Qing , Niu Ya , Zhang Feifei , Shao Ziyun , Ding Yanqing , Zhao Liang
Published: April 2023

Supplementary figure 1. Diagrammatic sketch showed major biological processes exerted by LASP1 using Gene Ontology. Supplementary Figure 2. LASP1 did not affect protein stability and ubiquitin-mediated degradation of S100A4. Supplementary Figure 3. LASP1 was correlated with S100A4 expression in CRC tissues. Supplementary figure 4. S100A4 was required for increasing the cell invasiveness of CRC cells induced by LASP1.
Supplemental figures 1 - 8 from Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer
Authors: Peter Stefan , Borkowska Edyta , Drayton Ross M. , Rakhit Callum P. , Noon Aidan , Chen Wei , Catto James WF
Published: April 2023

Supplemental figures 1 - 8. Supplemental figures reporting the distribution and fold changes of lncRNA in UCC, together with the outcomes from experiments to understand their function.
Supplementary data from In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma
Authors: Lussey-Lepoutre Charlotte , Bellucci Alexandre , Morin Aurélie , Buffet Alexandre , Amar Laurence , Janin Maxime , Ottolenghi Chris , Zinzindohoué Franck , Autret Gwennhael , Burnichon Nelly , Robidel Estelle , Banting Benjamin , Fontaine Sébastien , Cuenod Charles-André , Benit Paule , Rustin Pierre , Halimi Philippe , Fournier Laure , Gimenez-Roqueplo Anne-Paule , Favier Judith , Tavitian Bertrand
Published: April 2023

Figure S1- Phantom spectra of succinate at 4.7T and 3 T. Figure S2- SUCCES in Sdhb-/- allografted tumors in mice. Figure S3 - SUCCES in SDHx-mutated PPGL. Figure S4 - SUCCES in non SDHx-mutated PPGL.
Supplemental Figure S3 from The Renin–Angiotensin System Mediates EGF Receptor–Vitamin D Receptor Cross-Talk in Colitis-Associated Colon Cancer
Authors: Dougherty Urszula , Mustafi Reba , Sadiq Farhana , Almoghrabi Anas , Mustafi Devkumar , Kreisheh Maggi , Sundaramurthy Sumana , Liu Weicheng , Konda Vani J. , Pekow Joel , Khare Sharad , Hart John , Joseph Loren , Wyrwicz Alice , Karczmar Gregory S. , Li Yan Chun , Bissonnette Marc
Published: April 2023

Supplemental Figure S3. EGFR suppresses VDR expression in AOM rat tumors. VDR expression in control colonic mucosa and AOM-induced tumors in rats fed AIN-76A chow alone, or chow supplemented with EGFR inhibitor Gefitinib (A+G). Note the decreased VDR expression in tumors from rats fed AIN-76A alone, compared to rats supplemented with Gefitinib. Shown are representative tumors from two rats in each group.
Supplementary Figure 2 from Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
Authors: Luchman H. Artee , Stechishin Owen D.M. , Nguyen Stephanie A. , Lun Xueqing Q. , Cairncross J. Gregory , Weiss Samuel
Published: April 2023

Gefitinib inhibits growth of EGFRvIII and PTENwt BTICs.
Supplementary Figure 2 from Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
Authors: Zhang Libo , Marrano Paula , Wu Bing , Kumar Sushil , Thorner Paul , Baruchel Sylvain
Published: April 2023

Continued 3-day hypoxia does not increase cytotoxicity of evofosfamide compared to overnight hypoxia. A panel of two NBL cell lines (CHLA-20 and SK-N-BE(2)) and two rhabdomyosarcoma cell line (RH4 and RD) were selected to assess the effects of evofosfamide on cell proliferation in vitro. Cell viability was measured by Alamar Blue assays after exposing tumor cells to increasing concentrations of evofosfamide in vitro for 72 hours under normoxia, 1% O2 for 2 hours, 1% O2 overnight, or 1% O2 for three days. Dose-response curves were fit to the data by GraphPad Prism software.
Supplementary Table S2 from Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2
Authors: Terashima Masato , Togashi Yosuke , Sato Katsuaki , Mizuuchi Hiroshi , Sakai Kazuko , Suda Kenichi , Nakamura Yu , Banno Eri , Hayashi Hidetoshi , De Velasco Marco A. , Fujita Yoshihiko , Tomida Shuta , Mitsudomi Tetsuya , Nishio Kazuto
Published: April 2023

All mutations detected in the sample set (n = 50)